Table 2.
Baseline Characteristics and TOP1 copy number
| Total N (%) | TOP1 CN per cell | TOP1 CN per cell | Pearson Chi-Square test p | TOP1/CEN-20 ratio ≥ 2 N (%) | TOP1/CEN-20 ratio < 2 N (%) | Pearson Chi-Square test p | TOP1/CEN-2 ratio ≥ 2 N (%) | TOP1/CEN-2 ratio < 2 N (%) | Pearson Chi-Square test p | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| >median 4.46 No (%) | ≤ median 4.46 No (%) | ||||||||||
| Patients included | 108 (100) | 54 (50) | 54 (50) | 10 (9) | 98 (91) | 58 (54) | 50 (46) | ||||
| Gender | Males | 65 (60) | 35 (54) | 30 (46) | 0.33 | 6 (9) | 59 (91) | 0.99 | 37 (57) | 28 (43) | 0.41 |
| Females | 43 (40) | 19 (44) | 24 (56) | 4 (9) | 39 (91) | 21 (49) | 22 (51) | ||||
| Age | ≥65 | 52 | 23 (44) | 29 (56) | 0.25 | 4 (8) | 48 (92) | 0.59 | 26 (50) | 26 (50) | 0.46 |
| <65 | 56 | 31 (55) | 25 (45) | 6 (11) | 50 (89) | 32 (57) | 24 (43) | ||||
| WHO PS | 0 | 51 (47) | 25 (49) | 26 (51) | 0.99 | 5 (10) | 46 (90) | 0.95 | 25 | 26 | 0.33 |
| 1–2 | 53 (49) | 26 (49) | 27 (51) | 5 (9) | 48 (91) | 31 | 22 | ||||
| unknowna | 4 (4) | ||||||||||
| Location primary tumor | Right | 24 (22) | 13 (54) | 11 (46) | 0.82 | 1 (4) | 23 (96) | 0.36 | 10 (42) | 14 (58) | 0.32 |
| Left | 43 (40) | 22 (51) | 21 (49) | 6 (14) | 37 (86) | 23 (53) | 20 (47) | ||||
| Rectum | 41 (38) | 19 (46) | 22 (54) | 3 (7) | 38 (93) | 25 (61) | 16 (39) | ||||
| Primary tumor resected | Yes | 98 (91) | 48 (49) | 50 (51) | 0.51 | 7 (7) | 91 (93) | 0.02 | 51 (52) | 47 (48) | 0.28 |
| No | 10 (9) | 6 (60) | 4 (40) | 3 (30) | 7 (70) | 7 (70) | 3 (30) | ||||
| Number of metastatic sites | 1 | 37 (34) | 17 (46) | 20 (54) | 0.78 | 3 (8) | 34 (92) | 0.87 | 22 (59) | 15 (41) | 0.14 |
| 2 | 35 (33) | 19 (54) | 16 (46) | 4 (11) | 31 (89) | 14 (40) | 21 (60) | ||||
| >2 | 36 (33) | 18 (50) | 18 (50) | 3 (8) | 33 (92) | 22 (61) | 14 (39) | ||||
| Prior chemotherapy | F | 10 (9) | 7 (70) | 3 (30) | 0.10 | 3 (30) | 7 (70) | 0.054 | 9 (90) | 1 (10) | 0.01 |
| F + Oxa | 95 (88) | 47 (49) | 48 (51) | 7 (7) | 88 (93) | 49 (52) | 46 (48) | ||||
| F + Oxa + Bev | 3 (3) | 0 (0) | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 3 (100) | ||||
| Prior radiotherapy | Yes | 5 (5) | 2 (40) | 3 (60) | 0.65 | 0 (0) | 5 (100) | 0.47 | 4 (80) | 1 (20) | 0.23 |
| No | 103 (95) | 52 (50) | 51 (50) | 10 (10) | 93 (90) | 54 (52) | 49 (48) | ||||
| Liver metastases | Yes | 80 (74) | 43 (54) | 37 (46) | 0.19 | 8 (10) | 72 (90) | 0.65 | 43 (54) | 37 (46) | 0.99 |
| No | 28 (26) | 11 (39) | 17 (61) | 2 (7) | 26 (93) | 15 (54) | 13 (46) | ||||
| Lung metastases | Yes | 46 (43) | 25 (54) | 21 (46) | 0.44 | 3 (7) | 43 (93) | 0.40 | 24 (52) | 22 (48) | 0.78 |
| No | 62 (57) | 29 (47) | 33 (53) | 7 (11) | 55 (89) | 34 (55) | 28 (45) | ||||
Abbreviations: CN Copy number, F Fluorouracil (5-FU), Oxa Oxaliplatin, Bev Bevacizumab, HR Hazard ratio, CI Confidence interval